Media coverage about Tandem Diabetes Care (NASDAQ:TNDM) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.7928585698559 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Tandem inks distribution deal in Scandinavia for insulin pumps (massdevice.com)
- Reduced Time in Hypoglycemia Demonstrated in Tandem Diabetes Care’s Pivotal Trial for the t:slim X2 Insulin Pump … – Business Wire (press release) (businesswire.com)
- Tandem Diabetes Care Inc (TNDM) Expected to Announce Quarterly Sales of $36.10 Million (americanbankingnews.com)
- Global External Insulin Pumps Strategic Business Report 2015-2022: Key Players are Debiotech, F. Hoffmann-La Roche, , Insulet, Medtronic, Sooil Development & Tandem Diabetes Care (markets.financialcontent.com)
- Tandem Diabetes touts pivotal study of insulin pump with low glucose suspend feature (massdevice.com)
Tandem Diabetes Care (TNDM) traded up $0.02 during trading hours on Friday, hitting $2.43. 739,278 shares of the company were exchanged, compared to its average volume of 1,030,000. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. The company has a market cap of $24.59, a PE ratio of -0.12 and a beta of 0.44. Tandem Diabetes Care has a 52 week low of $2.14 and a 52 week high of $26.00.
In related news, Director Christopher J. Twomey purchased 75,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were bought at an average price of $2.00 per share, with a total value of $150,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Kim D. Blickenstaff purchased 750,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $1,500,000.00. The disclosure for this purchase can be found here. Insiders own 20.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/02/18/tandem-diabetes-care-tndm-receiving-somewhat-positive-media-coverage-study-finds.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.